Celltrion to sell 2 biosimilars through export subsidiaryThe Korean biopharmaceutical firm Celltrion Inc. said Friday that it has signed a deal with an affiliate to sell two biosimilars - Truxmia and Herzuma.
Under the deal, worth 151.4 billion won ($136.4 million) and equivalent to nearly 16 percent of the company’s annual sales, Celltrion will sell the biosimilars to Celltrion Healthcare, which handles Celltrion’s overseas business.
Truxima will be used in the treatment of diseases including rheumatoid arthritis and non-Hodgkin’s lymphoma, a type of leukemia.
Herzuma is a drug to treat breast cancer.
More in Industry
Samsung's Galaxy S21 series expected to outsell S20
Posco receives first shipment delivered by LNG carrier
Renault Samsung offers voluntary retirement as woes continue
SK Innovation acquires stake in Chinese BaaS operator
LG may hang up on smartphone business